Comprising more than 4,000 cancer researchers at more than 650 institutions across the United States and Canada, it is one of the largest of the NCI's clinical trial cooperative groups. Member institutions include 24 of the NCI-designated cancer centers, many university medical centers, private institutions, and Community Clinical Oncology Programs.
SWOG was created by the NCI in 1956 as the Southwest Cancer Chemotherapy Study Group (SWCCSG) and was headquartered in Houston, Texas. Its primary purpose was to study leukemia, a cancer of the blood which primarily affects children. Then in 1958, the NCI directed the SWCCSG to include the study of adult cancers, and separate administrative divisions were created for pediatric and adult cancers. The group's name was eventually changed to Southwest Oncology Group to reflect its new mission. Although in its early decades most SWOG member institutions were located in the Southwestern United States, the group spread to include members all over the United States and Canada. In 2010, in recognition of this national scope, the group dropped the regional qualifier from its name and adopted the acronym, SWOG, as its official name.
I'm not a product of your environment I don't hold these truths to be self-evident I don't necessarily hate the establishment but I don't think you really know what I meant what I said
"We at Agendia are thrilled and honored to be partnering with SWOG and the SWOG investigators in such an important endeavor, seeking new data to support our collective goals of optimizing treatment ...
"We at Agendia are thrilled and honored to be partnering with SWOG and the SWOG investigators in such an important endeavor, seeking new data to support our collective goals of optimizing treatment ...
SWOGCancer ResearchNetwork joins Caris' extensive network of leading cancer institutions and research consortia committed to improving patient outcomes through innovations in precision medicine ... Learn more at swog.org, and follow us on Twitter.
(MENAFN - PR Newswire). City of Hope (PRNewsfoto/City of Hope). Nivolumab added to AVD chemotherapy expected to become new standard for initial treatment for advanced stage disease in ... .
'SWOG clinical trials have changed the standards of cancer care by providing unbiased, well powered clinical studies to validate prescriptive outcomes that inform patient management guidelines', said Richard Paxman, CEO of Paxman.
(MENAFN - GlobeNewsWire - Nasdaq) IRVINE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- (Nasdaq. OCX), a precision diagnostics company with the mission to improve patient outcomes by providing ... .